New injection aims to retrain immune cells to fight arthritis
NCT ID NCT07349420
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a new drug called EF-M2 (Immutalon) in 48 adults with moderate-to-severe rheumatoid arthritis. The drug is designed to shift immune cells from a pro-inflammatory to an anti-inflammatory state. Participants received injections for 4 weeks, and researchers monitored safety and signs of immune changes. The goal is to see if this approach can control disease without needing lifelong medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EF-M2 (Immutalon), a drug injected under the skin to shift immune cells toward an anti-inflammatory state
What this could lead to
If it works, this could point toward a new way to control rheumatoid arthritis by calming overactive immune cells without long-term side effects.
What could go wrong
This is a very early, small trial (48 people) focused on safety, not proof of effectiveness. The drug may not work or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for New Medical Technologies
Novosibirsk, Novosibirsk Oblast, 630090, Russia